Stock Chart

EXEL

$58.39 +0.78%
Score: 43.4 HOLD
LEAPs: SELL $45
i
LEAPs Option Signal

Type: SELL growth_1yr
Strike: $45
Premium: $5.35
Expiry: Jan 15, 2027
Target: $39
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
Pro
Screener
Vol: 0.95x (vs SPY: 0.9x | vs QQQ: 0.9x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 02, 2026
Rising Wedge weak / forming — below our quality gate quality 60/100
A Rising Wedge is taking shape but hasn't passed our quality gate (60/100), so no projected path or levels are shown — only the forming rails on the chart below.
Historically breaks down 72% of the time; target hit in 78% of down-breaks (n=653)
Technical Chart
OVERLAYS
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER
SETTINGS
Active (2)
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About EXEL - Exelixis Inc

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Key Statistics

Market Cap $14B
P/E Ratio 18.22

More EXEL Analysis

Buy or Sell Analysis Price Prediction AI Analysis Fair Price Options Advisor Trendline Analysis

This EXEL stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track EXEL's price movements with trendlines, gamma walls, and key support/resistance levels.